Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib

Fig. 4

Correlation of tumor size, VAFmean and tumor markers. A correlation between VAFmean and tumor size at baseline (A) or after LEN treatment (B), and changes in tumor size and VAFmean-change(C) in Spearman’s rank correlation coefficient. A correlation between AFP/DCP and tumor size at baseline (D, G) or after LEN treatment (E, H). A correlation between changes in tumor size and in AFP/DCP before and after LEN treatment (F, I). Because the range of variation is large, the tumor markers are shown on a logarithmic scale (log2), and the change in tumor markers before and after LEN treatment is shown as a logarithmic scale (log2) of the ratio. After 4 weeks of LEN treatment, most cases showed a decrease in AFP (22/24, 92%) and an increase in DCP (19/24, 79%)

Back to article page